Common GLP-1 Side Effects: What Alabama Patients Should Know

GLP-1 medications can cause side effects — most commonly GI symptoms that improve over time. Understanding them helps Alabama patients and providers manage treatment well. Educational content only. Not medical advice. Always contact your provider about symptoms.

Most Common GLP-1 Side Effects

GI symptoms are the most frequently reported class of GLP-1 side effects. They are most common when starting treatment or increasing dose, and typically improve over time.

  • Nausea — most common early side effect, often improves within weeks. Eating smaller meals and avoiding high-fat foods may help.
  • Vomiting — less common than nausea but possible, especially early. Staying hydrated is important.
  • Diarrhea or constipation — GI changes are common during early GLP-1 use. Usually improve over time.
  • Decreased appetite — an intended effect. Eating regular, small, protein-rich meals prevents undereating.
  • Fatigue — some patients report low energy early in treatment. Hydration and adequate protein may help.
  • Injection site reactions — redness or minor irritation possible with injectable GLP-1 medications.
  • Headache — often related to reduced caloric intake or dehydration.

When to Contact Your Provider Immediately

  • Severe or persistent abdominal pain, especially if it radiates to the back
  • Rapid heart rate or heart palpitations
  • Signs of a severe allergic reaction (rash, swelling, difficulty breathing)
  • Severe nausea, vomiting, or diarrhea leading to dehydration

GLP-1 Side Effects: Common Questions

Are GLP-1 side effects dangerous?
Most are mild and temporary. Serious side effects are less common. Your provider discusses the full risk profile before prescribing.
Do GLP-1 side effects go away over time?
GI side effects commonly improve within the first several weeks as the body adjusts.
How do I reduce GLP-1 nausea?
Eating smaller, lower-fat meals, staying hydrated, and avoiding strong-smelling foods may help.

MEDICAL SOURCES & FURTHER READING

Read the original sources behind the medical topics on this page. Each entry identifies the claims it supports; a citation is not a review or approval of Alabama Trim Clinic or of every statement on this page.

  1. Semaglutide Injection: Drug InformationNIH / National Library of Medicine, MedlinePlusSupports: Prescribing precautions, gradual dose escalation, gastrointestinal symptoms and serious symptoms needing prompt medical attention for semaglutide injection.
  2. Tirzepatide Injection: Drug InformationNIH / National Library of Medicine, MedlinePlusSupports: Tirzepatide precautions, administration, dose escalation, common adverse effects and symptoms requiring urgent medical attention.
  3. Once-Weekly Semaglutide in Adults with Overweight or ObesityNew England Journal of Medicine / PubMedSupports: Semaglutide 2.4 mg trial efficacy and gastrointestinal adverse effects in adults without diabetes, alongside lifestyle intervention; not outcomes for this clinic or compounded products.
  4. Tirzepatide Once Weekly for the Treatment of ObesityNew England Journal of Medicine / PubMedSupports: Tirzepatide's GIP/GLP-1 mechanism, dose-dependent trial weight reduction and gastrointestinal adverse effects in the 72-week SURMOUNT-1 study; not clinic-specific results.
  5. Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity SocietyObesity / PubMedSupports: Individualized nutrition, adequate protein, resistance exercise, muscle preservation, management of gastrointestinal symptoms and ongoing assessment during GLP-1 treatment.
  6. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight LossFDASupports: Compounded GLP-1 drugs are not FDA-approved; dosing errors, salt forms, storage and shipping concerns; patient-specific need and licensed pharmacy precautions.
RESEARCH & REFERENCES

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Wilding JPH, Batterham RL, Calanna S, et al. New England Journal of Medicine, 2021.

Research published in New England Journal of Medicine reported greater average weight reduction with once-weekly semaglutide 2.4 mg plus lifestyle intervention than with placebo in the STEP 1 trial. Gastrointestinal adverse effects occurred. Trial results are not a prediction of an individual's response.

Tirzepatide Once Weekly for the Treatment of Obesity

Jastreboff AM, Aronne LJ, Ahmad NN, et al. New England Journal of Medicine, 2022.

Research published in New England Journal of Medicine reported greater average weight reduction with tirzepatide than placebo in SURMOUNT-1, with gastrointestinal events commonly reported during dose escalation. Participants and trial conditions may differ from routine care.

Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society

Mozaffarian D, Agarwal M, Aggarwal M, et al. Obesity, 2025.

Research published in Obesity reported a literature-based clinical advisory identifying nutrition, resistance exercise and individualized medical follow-up as priorities during GLP-1 therapy. This is an advisory, not a trial proving a single protein target or guaranteed muscle preservation.

Published research describes the studied population and formulation, not guaranteed individual results, clinic outcomes or evidence that compounded products are equivalent.

General education only, not individualized medical advice. Prescription treatment requires evaluation by a licensed provider. Eligibility, medication and dosing depend on individual circumstances.

Where It All Began

South Florida Trim Clinic in Naples, Florida, is where Trim Clinic Network began. Alabama Trim Clinic brings that commitment to personalized care through telehealth with licensed medical providers. No membership fees ever. Treatment and prescribing depend on an individual medical evaluation and provider licensure in the patient’s state.